# AstraZeneca invests $3.5B in US R&D and manufacturing

AstraZeneca announced $3.5 billion of capital investment in the United States to expand its research and manufacturing footprint by the end of 2026. This includes $2 billion of new investment creating over a thousand jobs, with projects in Massachusetts, Maryland, and Texas.

- Type: Investment
- Announced: 2024-11-12
- Where: Kendall Square, Cambridge, Massachusetts; Maryland; West and East Coasts; Texas, United States
- Value: $3.50B
- Jobs: 1,000
- Starts operating: 2026
- Status: announced
- Products: biologics, cell therapies, specialty pharmaceuticals
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [AstraZeneca](https://endata.com/companies/35467.md)

## Sources

- [astrazeneca.com](https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-invests-3bn-500mn-in-us.html), 2024-11-12: "Our multibillion dollar investment reflects the attractiveness of the business environment together with the quality of talent and innovation capabilities here in the United States."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.